2 weeks Ago By ABMN Staff
The Manufacturers Life Insurance Company lifted its position in AbbVie Inc. ( NYSE:ABBV – Free Report ) by 17.0% in the second quarter, according to its most recent Form 13F filing with the SEC.
The firm owned 2,299,164 shares of the company’s stock after purchasing an additional 334,184 shares during the period. The Manufacturers Life Insurance Company’s holdings in AbbVie were worth $394,353,000 at the end of the most recent quarter. Other institutional investors also recently bought and sold shares of the company.
West Coast Financial LLC increased its holdings in AbbVie by 9.7% during the first quarter. West Coast Financial LLC now owns 1,578 shares of the company’s stock valued at $287,000 after buying an additional 140 shares during the period.
FCG Investment Co purchased a new position in shares of AbbVie in the 1st quarter valued at $1,413,000. Safeguard Financial LLC bought a new position in shares of AbbVie in the 1st quarter worth $235,000. BluePath Capital Management LLC lifted its stake in shares of AbbVie by 0.
9% during the 1st quarter. BluePath Capital Management LLC now owns 7,311 shares of the company’s stock worth $1,331,000 after purchasing an additional 67 shares during the last quarter. Finally, Voisard Asset Management Group Inc.
bought a new stake in AbbVie during the fourth quarter valued at about $87,000. 70.23% of the stock is currently owned by hedge funds and other institutional investors.
AbbVie Trading Up 0.4 % Shares of AbbVie stock opened at $191.93 on Friday.
The firm has a 50-day simple moving average of $190.68 and a two-hundred day simple moving average of $176.07.
The company has a debt-to-equity ratio of 8.51, a quick ratio of 0.71 and a current ratio of 0.
81. AbbVie Inc. has a fifty-two week low of $135.
85 and a fifty-two week high of $199.95. The company has a market cap of $338.
92 billion, a P/E ratio of 56.95, a price-to-earnings-growth ratio of 2.65 and a beta of 0.
64. AbbVie Dividend Announcement The firm also recently announced a quarterly dividend, which will be paid on Friday, November 15th. Stockholders of record on Tuesday, October 15th will be given a dividend of $1.
55 per share. The ex-dividend date is Tuesday, October 15th. This represents a $6.
20 dividend on an annualized basis and a dividend yield of 3.23%. AbbVie’s dividend payout ratio (DPR) is 183.
98%. Insider Buying and Selling In related news, Chairman Richard A. Gonzalez sold 66,500 shares of the company’s stock in a transaction dated Monday, August 5th.
The shares were sold at an average price of $186.52, for a total transaction of $12,403,580.00.
Following the completion of the transaction, the chairman now owns 446,599 shares in the company, valued at approximately $83,299,645.48. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website .
In related news, Chairman Richard A. Gonzalez sold 66,500 shares of the stock in a transaction on Monday, August 5th. The stock was sold at an average price of $186.
52, for a total value of $12,403,580.00. Following the completion of the transaction, the chairman now directly owns 446,599 shares of the company’s stock, valued at approximately $83,299,645.
48. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website . Also, Chairman Richard A.
Gonzalez sold 282,845 shares of AbbVie stock in a transaction on Wednesday, July 17th. The stock was sold at an average price of $175.00, for a total transaction of $49,497,875.
00. Following the sale, the chairman now directly owns 513,099 shares in the company, valued at approximately $89,792,325. The disclosure for this sale can be found here .
0.25% of the stock is owned by insiders. Analyst Ratings Changes Several research firms have commented on ABBV.
Cantor Fitzgerald reissued an “overweight” rating and set a $200.00 price target on shares of AbbVie in a research report on Monday, August 5th. HSBC raised shares of AbbVie from a “hold” rating to a “buy” rating and set a $185.
00 target price for the company in a research report on Wednesday, June 5th. Piper Sandler lifted their price target on shares of AbbVie from $196.00 to $209.
00 and gave the stock an “overweight” rating in a report on Friday, August 23rd. Barclays increased their price objective on AbbVie from $187.00 to $200.
00 and gave the company an “overweight” rating in a report on Friday, July 26th. Finally, Morgan Stanley boosted their target price on AbbVie from $211.00 to $218.
00 and gave the stock an “overweight” rating in a research note on Monday, August 12th. Two research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.
com, AbbVie has an average rating of “Buy” and a consensus target price of $191.64. Get Our Latest Analysis on ABBV About AbbVie ( Free Report ) AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide.
The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. Featured Stories Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc.
( NYSE:ABBV – Free Report ). Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter .
.
